<DOC>
	<DOC>NCT00686777</DOC>
	<brief_summary>The objective is to evaluate the efficacy and safety of the combination therapy with subcutaneous (SC) Pegylated Interferon (PEG-IFN) alfa-2b 1.5 ug/kg/week plus low-dose ribavirin administered for 48 weeks in participants with chronic hepatitis C virus (HCV) who are infected with HCV genotype 1 high viral load, and weigh 50 kg or less.</brief_summary>
	<brief_title>Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Diagnosed with chronic hepatitis C. Minimum 20 years of age Willing to use adequate contraception during the course of the study. Participants who can be hospitalized for at least 14 days since treatment initiation. Positive for HCV genotype 1 (genotype 1a and 1b) with high viral load (HCVRNA &gt;=100 kIU/mL). Participants weighing over 40 kg to 50 kg. Hematology results of: hemoglobin levels &gt;=12 g/dL neutrophils &gt;=1,500/mm^3 platelets &gt;=100,000/mm^3 Previous ribavirin therapy. Previous interferon therapy within 90 days of registration. Participants who received treatment with injectable products containing glycyrrhizin/cysteine/glycine (Stronger NeoMinophagen C, etc.), Shosaikoto, or ursodeoxycholic acid within 30 days before the start of treatment Participants who received treatment with an antiviral or antitumor drug or who received immunomodulating therapy (including steroids and radiotherapy) within 90 days before the start of treatment [excluding local administration and topical drugs]. Participants who received other investigational drugs within 180 days before the start of treatment. Hepatitis Bs (HBs) antigenpositive Antinuclear antibodies &gt;=1:160 Fasting blood glucose &gt;=110 mg/dL (however, participants with fasting blood glucose of 110 mg/dL to &lt;126 mg/dL can be registered if HbA1c is &lt;6.5%) Participants diagnosed with liver cirrhosis in most recent celioscopy or liver biopsy. Participants with or who have a history of any of the following: liver failure; hepatic encephalopathy, esophageal varices, or ascites; depression or schizophrenia requiring treatment or suicidal attempt or ideation; epileptic seizures requiring drug treatment; autoimmune disease (such as Hashimoto's disease, Crohn's disease, ulcerative colitis, chronic rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic erythematosus, autoimmune hemolytic anemia, and scleroderma); hepatic cancer Participants with any of the following: liver disease such as autoimmune hepatitis, alcoholic liver disease, and druginduced hepatic impairment; hemophilia; arrhythmia requiring treatment and participants with or who have a history of angina pectoris, cardiac failure, myocardial infarction, or lifethreatening arrhythmia; hypertension (systolic BP of 160 mmHg or more and diastolic BP of 100 mmHg or more) not possible to control with drug therapy; chronic pulmonary disease; hemoglobinopathy (thalassemia, sickle cell anemia); malignant tumor or who have a history of malignant tumor within the past 5 years; thyroid function disorder not controlled by drug therapy. Participants with organ transplants (excluding cornea and hair transplants). Participants with a history of hypersensitivity to interferon preparations, nucleoside analogs, or biological products such as vaccine. Participants with a specific response to PEGIFN alfa2b in a prick test to be conducted just before the initiation of treatment. Participants who are pregnant or nursing (in the case of male Participants : partner is pregnant)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis C</keyword>
</DOC>